Investigational drug reduces heart damage during angioplasty

March 12, 2013

A single dose of an investigational anti-inflammatory drug, inclacumab, reduced damage to heart tissue during angioplasty in a study presented today at the American College of Cardiology's 62nd Annual Scientific Session.

More than 1 million coronary angioplasty procedures are performed in the United States each year, at a cost of more than $10 billion. can be damaged during angioplasty, often leading to additional procedures, poor outcomes and higher .

In this trial, researchers compared a single dose of inclacumab administered one hour before angioplasty with a placebo.

Inclacumab is a that blocks p-selectin, a molecule found in platelets and the cells that line blood vessels. P-selectin is activated in response to inflammation, which can ultimately lead to . The study met its primary endpoint: decrease in levels of troponin I, a protein found in the bloodstream when heart damage has occurred, after angioplasty.

"Our hypothesis was that by using the p-selectin antagonist inclacumab, we'd be able to demonstrate vascular benefit," said Jean-Claude Tardif, MD, director of the Research Centre at the Montreal Heart Institute, professor of medicine at the University of Montreal and the study's lead investigator.

The SELECT- phase II trial involved 530 with a median age of 61 experiencing a type of called non-ST-elevation or NSTEMI. Patients were randomized to receive an infusion of inclacumab at 20 mg/kg, inclacumab at 5 mg/kg or placebo one hour before angioplasty.

Researchers measured using two standard : troponin I and CK-MB. These markers are used clinically to diagnose heart attacks. They were measured at baseline and at eight, 16 and 24 hours after PCI. The co-primary endpoints were the change in troponin I at 16 hours and 24 hours.

In patients receiving 20 mg/kg of inclacumab, troponin I levels dropped 22.4 percent more at 16 hours (p=0.066) and 24.4 percent more at 24 hours (p=0.05), compared with patients on placebo. CK-MB levels dropped 16.3 percent more at 16 hours (p=0.088) and 17.4 percent more at 24 hours (p=0.055), compared with patients on placebo.

Also, at 24 hours after angioplasty, 18.3 percent of patients on placebo had CK-MB increases of more than three times the upper limit of normal, a threshold that many clinical trials use to define a post-angioplasty heart attack. This compared with 8.9 percent of patients who received the higher dose of inclacumab (p=0.051).

The 5 mg/kg dose of inclacumab had no significant effects on the cardiac markers. Researchers also measured p-selectin levels to see if they correlated with changes in CK-MB and troponin I. Levels did not drop significantly in the group that received 5 mg/kg inclacumab. However, levels dropped 19.2 percent with the 20 mg/kg inclacumab dose, compared with placebo (p=0.0002).

"It was exciting to see that a single administration of inclacumab would yield clinical benefit," Dr. Tardif said.

The researchers analyzed a subgroup of patients who were not taking antiplatelet drugs called glycoprotein 2b3a inhibitors. These are given to some patients to prevent blood clots but can increase the risk of bleeding. In patients not taking 2b3a inhibitors, those who received the 20 mg/kg dose of inclacumab experienced a 36 percent decrease in troponin I at 24 hours (p=0.008 compared with placebo).

"If we're able to confirm these results in potential future studies, this drug could become part of the therapeutic armamentarium in modern cardiology," Dr. Tardif said. "You could use this drug more widely, in all patients coming in with heart attacks, although that would require additional large studies."

Explore further: New drug inclacumab reduces heart damage

More information: Dr. Tardif will present the study "Effects of the P-Selectin Antagonist Inclacumab in the Select-Acute Coronary Syndromes Trial" on Sunday, March 10 at 11:21 a.m., in Moscone Center, South, Esplanade Ballroom.

Related Stories

New drug inclacumab reduces heart damage

March 10, 2013

A single dose of an investigational anti-inflammatory drug called inclacumab considerably reduces damage to heart muscle during angioplasty (the opening of a blocked artery), according to a recent international clinical trial ...

Recommended for you

Macrophages shown to be essential to a healthy heart rhythm

April 20, 2017

A Massachusetts General Hospital (MGH)-led research team has identified a surprising new role for macrophages, the white blood cells primarily known for removing pathogens, cellular debris and other unwanted materials. In ...

3-D-printed patch can help mend a 'broken' heart

April 14, 2017

A team of biomedical engineering researchers, led by the University of Minnesota, has created a revolutionary 3D-bioprinted patch that can help heal scarred heart tissue after a heart attack. The discovery is a major step ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

not rated yet Mar 13, 2013
You significantly overstate the number of angioplasties in the US annually. The number never exceeded a million and is down to about 650k per year now. AHA used to count balloon deployments and stent placements as two different things when in reality they are the same procedure 95% of the time. AHA still goofs up some. Use their source data, CDC. More back-up information available, just email me at wpowell at

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.